Previous 10 | Next 10 |
Stealth BioTherapeutics Corp (MITO) Q1 2021 Earnings Conference Call May 18, 2021, 08:30 AM ET Company Participants Henry Hess - Chief General Counsel Reenie McCarthy - CEO Jim Carr - Chief Clinical Development Officer Brian Blakey - Chief Commercial Officer Rob Weiskopf - CFO Conference Call...
Stealth BioTherapeutics (MITO) +31% on Q1 results.Ultralife Corporation (ULBI) +22% on new contract from U.S. Army.China HGS Real Estate Inc. (HGSH) +14% on Q2 results.XpresSpa Group (XSPA) +9% on Q1 results.Reliance Global Group (RELI) +8%.Express (EXPR) +7%.Eloxx Pharmac...
Stealth BioTherapeutics Reports First Quarter 2021 Financial Results And Recent Business Highlights Phase 3 randomized withdrawal trial for cardiomyopathy in Barth planned ReCLAIM Phase 1 data presented at ARVO 2021 supports ReCLAIM-2 Phase 2 geographic atrophy trial design;...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back once again, investors! We’re ready to get right back into covering the stock market today and there’s plenty to talk about. Let’s start the day off with the biggest pre-market stock movers ...
Stealth BioTherapeutics Announces Additional Development Financing to Advance Elamipretide Clinical Trials Stealth to receive $30 million in additional payments during 2021 PR Newswire BOSTON , May 17, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq...
Stealth BioTherapeutics Announces Poster Presentation at American College of Cardiology (ACC) Annual Meeting PR Newswire BOSTON , May 17, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the ...
Stealth BioTherapeutics to Present at Upcoming Investor Conferences in May PR Newswire BOSTON , May 13, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commerc...
Stealth BioTherapeutics to Report First Quarter Financial Results on Tuesday, May 18, 2021 PR Newswire BOSTON , May 11, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, developm...
Soligenix (SNGX) -22% as company now plans to submit the NDA in the 1H22.LM Funding America (LMFA) -11%.Senmiao Technology (AIHS) -7%.InnSuites Hospitality (IHT) -5%.Ra Medical Systems (RMED) -6%.Galapagos (GLPG) -5%.Stealth BioTherapeutics (MITO) -5%.Luokung Technology (LKCO) -5%. For...
ChemoCentryx (CCXI) -49% after FDA panel split 9-9 on efficacy for Chemocentryx's vasculitis candidate avacopan and reports outcome of FDA’s expert panel meeting on avacopan.Orphazyme (ORPH) -28% after arimoclomol flunks late-stage amyotrophic lateral sclerosi...
News, Short Squeeze, Breakout and More Instantly...
Stealth BioTherapeutics Corp. Company Name:
MITO Stock Symbol:
NYSE Market:
Stealth BioTherapeutics Corp. Website:
Stealth BioTherapeutics Corp Announces Completion of Merger PR Newswire BOSTON , Nov. 16, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) (the "Company" or "Stealth BioTherapeutics"), a clinical-stage biotechnology company focused on the ...
Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) PR Newswire SBT-272 Phase 1 safety and tolerability data support further clinical development SBT-272 was neuroprotective...
Stealth BioTherapeutics Corp to Hold Extraordinary General Meeting of Shareholders PR Newswire BOSTON , Oct. 7, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused o...